Lorcaserin and metabolic disease: weight-loss dependent and independent effects.

Harold E BaysC PerdomoE NikonovaR KnothM Malhotra

Published in: Obesity science & practice (2018)

Across Phase III clinical trials, lorcaserin 10 mg BID improved multiple cardiometabolic parameters through both weight-loss dependent and independent mechanisms.

Keyphrases

weight loss
phase iii
clinical trial
bariatric surgery
open label
roux en y gastric bypass
phase ii
gastric bypass
double blind
placebo controlled
glycemic control
weight gain
type diabetes
body mass index